US 9422556
RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis
granted A61PA61P27/00A61P27/02
Quick answer
US patent 9422556 (RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis) held by Arrowhead Pharmaceuticals, Inc. expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Aug 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61P, A61P27/00, A61P27/02, A61P35/00